These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7308336)

  • 21. Cerebrospinal fluid and serum concentrations of rifampin in meningeal tuberculosis after intravenous administration.
    Mikhail IA; Girgis NI; Bourgeois LA; Lissner CR
    Chemioterapia; 1987 Jun; 6(2 Suppl):309-10. PubMed ID: 3509425
    [No Abstract]   [Full Text] [Related]  

  • 22. Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis.
    Mahajan M; Rohatgi D; Talwar V; Patni SK; Mahajan P; Agarwal DS
    J Commun Dis; 1997 Sep; 29(3):269-74. PubMed ID: 9465533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
    Saballs M; Pujol M; Tubau F; Peña C; Montero A; Domínguez MA; Gudiol F; Ariza J
    J Antimicrob Chemother; 2006 Sep; 58(3):697-700. PubMed ID: 16895941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Local therapeutic trials of various forms of extrapulmonary tuberculosis using rifampicin suspension].
    Basacopol A; Burzoni FJ; Munteanu E
    Maroc Med; 1974 May; 54(579):314-6. PubMed ID: 4444315
    [No Abstract]   [Full Text] [Related]  

  • 25. Adverse reactions during rifampicin treatment.
    Riska N; Mattson K
    Scand J Respir Dis; 1972; 53(2):87-96. PubMed ID: 5052728
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of pulmonary tuberculosis of native Black Africans a chemotherapeutic regime including rifampicin (apropos of 75 patients)].
    Ayad M; Hane A; Kane PA
    Dakar Med; 1980; 25(1):65-74. PubMed ID: 7460740
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pharmacokinetics of intravenous rifampicin (RMP) and its clinical evaluation in purulent bacterial meningitis].
    Di Nola F; Eandi M; Soranzo ML; Capra E; Bosio G; Bramato C; Salassa B; Bendiscioli L
    Minerva Med; 1981 Apr; 72(14):875-92. PubMed ID: 7219797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rifampicin blood levels in man.
    Verbist L
    Acta Tuberc Pneumol Belg; 1969; 60(3):288-98. PubMed ID: 5373653
    [No Abstract]   [Full Text] [Related]  

  • 29. Bioequivalence study of rifampicin in fixed-dose combination of rifampicin and isoniazid vs. separate formulations.
    Panchagnula R; Singh I; Kaur KJ; Kaul CL
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):625-8. PubMed ID: 10669909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parenteral rifampicin in tuberculous and severe non-mycobacterial infections. Clinical data on 237 patients.
    Kissling M; Bergamini N; Xilinas M
    Chemotherapy; 1982; 28(3):229-39. PubMed ID: 7094664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Preliminary note on the use of parenteral rifampicin (slow venous infusion). Blood levels and tolerance].
    Giura R; Scardaccione M; Roccamo B; Giura C
    G Ital Chemioter; 1978; 25(1):45-8. PubMed ID: 751848
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pharmacokinetics of rifampicin in single and repeated administration to patients with inflammatory processes in the lungs of nontuberculotic etiology].
    Makarenkova RV; Kopeiko IP
    Antibiotiki; 1977 Mar; 22(3):259-60. PubMed ID: 848920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse drug reactions observed during DOTS.
    Dhingra VK; Rajpal S; Aggarwal N; Aggarwaln JK; Shadab K; Jain SK
    J Commun Dis; 2004 Dec; 36(4):251-9. PubMed ID: 16506547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rifampicin in dermatology and venereology].
    Ayala L
    G Ital Dermatol Minerva Dermatol; 1969 Dec; 44(12):665-72. PubMed ID: 5395529
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of rifampicin serum concentrations in men, following drug administration before or after breakfast.
    Hussels H
    Acta Tuberc Pneumol Belg; 1969; 60(3):270-5. PubMed ID: 5371664
    [No Abstract]   [Full Text] [Related]  

  • 36. Rimactan parenteral formulation in clinical use.
    Kissling M; Xilinas M
    J Int Med Res; 1981; 9(6):459-9. PubMed ID: 7319132
    [No Abstract]   [Full Text] [Related]  

  • 37. Ethambutol in paediatric tuberculosis: aspects of ethambutol serum concentration, efficacy and toxicity in children.
    Thee S; Detjen A; Quarcoo D; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2007 Sep; 11(9):965-71. PubMed ID: 17705973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rifampicin serum levels in childhood tuberculosis.
    Thee S; Detjen A; Wahn U; Magdorf K
    Int J Tuberc Lung Dis; 2009 Sep; 13(9):1106-11. PubMed ID: 19723399
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets.
    Nijland HM; L'homme RF; Rongen GA; van Uden P; van Crevel R; Boeree MJ; Aarnoutse RE; Koopmans PP; Burger DM
    AIDS; 2008 May; 22(8):931-5. PubMed ID: 18453852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison between doxycycline-rifampin-amikacin and doxycycline-rifampin regimens in the treatment of brucellosis.
    Ranjbar M; Keramat F; Mamani M; Kia AR; Khalilian FO; Hashemi SH; Nojomi M
    Int J Infect Dis; 2007 Mar; 11(2):152-6. PubMed ID: 16798042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.